Results 41 to 50 of about 219,417 (396)
Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer
New England Journal of Medicine, 2019 BACKGROUND Darolutamide is a structurally unique androgen‐receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic ...
K. Fizazi +13 more
semanticscholar +1 more source
A study protocol for a comparative effectiveness evaluation of antiandrogenic medications against Standard of Care [PDF]
arXiv, 2021 This paper presents a study protocol for an effectiveness evaluation of antiandrogenic (NAM) medications (i.e. abiraterone acetate and enzalutamide) against standard of care in patients suffering from metastatic castrate resistant prostate cancer.
arxiv
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. [PDF]
, 2016 Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone.
Armstrong, Cameron +4 more
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sex is a prominent risk factor for abdominal aortic aneurysms (AAAs), and angiotensin II (Ang II) induces AAA formation to a greater degree in male than in female mice.
Kamalika Mukherjee +6 more
doaj +1 more source
Clinical Cancer Research, 2020 Purpose: The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear. Experimental Design: In patients with metastatic castration-sensitive prostate cancer at a tertiary referral center ...
K. Stopsack +16 more
semanticscholar +1 more source
, 2022 Cancer Communications, Volume 42, Issue 12, Page 1407-1411, December 2022.
Chao Liu +9 more
wiley +1 more source
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]
, 2016 Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H +17 more
core +1 more source
Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer
New England Journal of Medicine, 2018 BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA) level are at high risk for metastasis.
M. Hussain +11 more
semanticscholar +1 more source
Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
IJU Case Reports, Volume 6, Issue 1, Page 37-40, January 2023., 2023 Introduction Several prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum‐based therapy can be used to predict the efficacy of poly(adenosine diphosphate‐ribose) polymerase inhibitors such as olaparib.
Yoshiyuki Miyazawa +9 more
wiley +1 more source